TORONTO, Sept. 9 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that RiskMetrics ISS Canada, Canada's leading independent
proxy firm, has indicated that they have no objection to the transaction, and
are recommending that ARIUS shareholders and warrant holders vote FOR the
proposed plan of arrangement whereby Roche will acquire all of ARIUS'
outstanding shares and warrants.
"The comprehensive review undertaken by RiskMetrics ISS Canada recommends
that ARIUS shareholders and warrant holders vote FOR the Arrangement and, in
our opinion, provides significant independent validation that the transaction
represents the best option for maximizing shareholder value," said Dr. David
S. Young, President and Chief Executive Officer of ARIUS.
A special meeting of ARIUS shareholders and warrant holders will be held
at 10:30 a.m. Eastern Time on September 16, 2008 at the Suites at 1 King West,
Toronto, Ontario, Canada, M5H 1A1. ARIUS shareholders and warrant holders are
encouraged to review the Notice of Special Meeting and Information Circular
issued by the Company on August 12, 2008. The Information Circular provides,
among other things, a detailed discussion of the process that led to the
proposed Arrangement and the reasons behind ARIUS Board of Directors'
unanimous recommendation that shareholders vote FOR the transaction. Pending
the receipt of court and shareholder approval, the transaction is expected to
be completed in late September.
ARIUS' Board asks shareholders and warrant holders to vote their proxy
FOR the proposed Arrangement today by signing, dating and returning their
proxies. The deadline for receiving proxies is September 12, 2008 at 5:00 p.m.
Eastern Time. If shareholders have any questions about the information
contained in the Information Circular or require assistance in completing
their proxy forms, please contact ARIUS' proxy solicitation agent, The Laurel
Hill Advisory Group, toll-free at 1-888-270-2614.
ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 500
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusmabs.com
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
firstname.lastname@example.org, email@example.com; James Smith, Investor
Relations, (416) 815-0700 ext. 229, firstname.lastname@example.org